Peng joined Sofinnova in 2019 as Analyst for the Public Equity team. He focuses on public investments biotech and pharmaceutical companies.
Before joining Sofinnova, Peng worked as a sell-side associate for three years at Bank of America and Stifel, where he focused on biotech and pharmaceutical companies. Prior to this, Peng was a graduate student at University of Texas Southwestern Medical Center (UTSW) in the laboratory of Dr. Kim Orth to identify novel mechanisms of bacterial infection.
Peng received his Ph.D. in Biomedical Sciences from UTSW. Peng also earned his B.S. with Honors in Biology from Jinan University in China and was awarded the National Scholarship.